Mirum Pharmaceuticals reported an insider transaction involving Senior Vice President and Global Controller Jolanda Howe. On March 16, 2026, Howe sold 4,732 shares of Mirum common stock at a per-share price of $91.9779, producing gross proceeds of $435,239.
The insider activity followed an exercise of performance restricted stock units on March 15, 2026. Under that exercise, Howe converted two tranches of PRSUs into common stock - 2,658 units in one tranche and 6,000 units in another. After the sale and the conversions, Howe is recorded as directly owning 8,429 shares of Mirum Pharmaceuticals.
These transactions take place against a backdrop of strong share-price performance for Mirum. The stock has risen 114% over the past 12 months and was trading at $96.60 at the time of the latest reporting. InvestingPro analysis cited in the company filings and market commentary indicates the stock appears overvalued relative to its Fair Value estimate and placed Mirum on a Most Overvalued list. The InvestingPro note also references 13 additional ProTips and a full Pro Research Report available to subscribers for deeper analysis.
Operationally, Mirum has reported several clinical development and enrollment milestones. The company completed enrollment in its Phase 3 EXPAND study, which is evaluating LIVMARLI for the treatment of cholestatic pruritus in patients with rare liver diseases. The EXPAND program is intended to assess potential use of LIVMARLI beyond the currently targeted indications of Alagille syndrome and PFIC, with Mirum noting the study could broaden the addressable patient population to more than 1,000 patients across the U.S. and the EU.
Mirum also announced progress in its hepatitis delta virus program. The company has completed the Phase 3 AZURE 1 study and is in the screening phase for the Phase 3 AZURE 4 study, marking enrollment milestones in that development pathway.
On the financial side, Mirum reported fourth-quarter results for 2025 and maintained its fiscal year 2026 product sales guidance of $630 million to $650 million. The company said 2025 sales for LIVMARLI totaled $360 million, representing 69% year-over-year growth in that product's revenue.
Market participants have reacted with a range of analyst ratings and price targets. Citizens reaffirmed a Market Outperform rating and a $132.00 price target. Morgan Stanley reiterated an Overweight rating with a $130.00 target. Evercore ISI raised its target to $126, citing pipeline progress. Leerink Partners lowered its price target to $118 while maintaining an Outperform rating.
The combination of insider selling, a significant share-price rally, analyst target dispersion, and the company’s clinical and sales updates gives investors multiple data points to weigh when assessing Mirum’s near-term outlook and valuation.